AU
UK
CA
NZ
IND
US
BioSig Technologies, Inc. (Nasdaq: BSGM) has signed a definitive share exchange agreement with Streamex Exchange Corporation, a private company focused on tokenizing real-world assets, particularly commodities. The agreement will result in Streamex becoming a wholly owned subsidiary of BioSig through an exchange of Streamex …
Moderna, Inc. (NASDAQ: MRNA) has submitted an application to the U.S. Food and Drug Administration (FDA) seeking review and authorization for its updated COVID-19 vaccine formula, Spikevax 2025-2026. The new formulation is designed specifically to target the SARS-CoV-2 variant LP.8.1.
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, has entered into definitive agreements for a private placement involving the issuance and sale of 7,222,223 shares of its common stock—or pre-funded warrants in lieu thereof—along with short-term warrants to purchase up to 14,444,446 shares of …
Invivyd, Inc. (Nasdaq: IVVD) announced that its monoclonal antibody PEMGARDA® (pemivibart) has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. The update identifies PEMGARDA as a potential pre-exposure prophylaxis (PrEP) option against COVID-19 for patients …
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) presented new long-term data from its Phase 2 TELLOMAK trial evaluating lacutamab in Sézary syndrome (SS) and mycosis fungoides (MF) at the ASCO 2025 Annual Meeting. The findings, as of the October 17, 2024 data cut-off, …
Sanofi (NASDAQ: SNY)is a global healthcare company focused on developing medicines and vaccines, with an emphasis on innovation, sustainability, and social responsibility. They company has announced a definitive agreement to acquireVigil Neuroscience, Inc. (NASDAQ: VIGL), a clinical-stage biotechnology company focused on treatments for neurodegenerative …
Polyrizon Ltd. (Nasdaq: PLRZ), a biotech firm focused on intranasal hydrogel technologies, has released findings from recent ex vivo studies demonstrating key performance characteristics of its proprietary formulation. The tests focused on two critical aspects: surface coverage and mucoadhesion—both fundamental to the platform’s intended …
Weave (NYSE: WEAV)has completed its acquisition of TrueLark, an AI-based front-desk automation and receptionist platform, advancing its broader strategy of integrating artificial intelligence into healthcare communications. The deal represents a step forward in Weave’s focus on expanding its offerings for small and medium-sized healthcare …
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a company specializing in the development and commercialization of medicines targeting infectious diseases, announced its financial results for the first quarter ended March 31, 2025. The results highlighted continued revenue growth and product traction, particularly in the …
CureVac N.V. (NASDAQ: CVAC), a global biopharmaceutical leader in messenger RNA (mRNA) innovation, has secured another key legal victory in its ongoing patent litigation against BioNTech SE. The European Patent Office (EPO) has upheld the validity of CureVac’s European patent EP 4 023 755 …
Please wait processing your request...